Take the Zacks Approach to Beat the Markets: Macy's, United Natural Foods & Monster Beverage in Focus
Macy's climbs after a Zacks upgrade as multiple portfolios showcase strong gains across UNFI, Monster Beverage and other standout stocks.
Here's Why Cencora ( COR ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Cencora ( COR ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
If You Invested $100 In Cencora Stock 5 Years Ago, You Would Have This Much Today - Cencora ( NYSE:COR )
Cencora ( NYSE:COR ) has outperformed the market over the past 5 years by 14.68% on an annualized basis producing an average annual return of 28.31%. Currently, Cencora has a market capitalization of $70.94 billion.
Is State Street SPDR Russell 1000 Low Volatility Focus ETF ( ONEV ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Why Cencora ( COR ) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Rigetti Computing to Post Q3 Earnings: What's in Store for the Stock?
RGTI's Q3 results are likely to gain from U.S. funding clarity, new contracts and gains from its next-gen quantum system.
COR Q4 Earnings & Revenues Beat Estimates, Gross Margin Improves
Cencora's Q4 results top estimates with 15% EPS growth and stronger margins, as GLP-1 demand and the RCA acquisition fuel solid segment gains.
Cencora ( COR ) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.Nov. 5, 2025 at 8:30 a.m. ETPresident and Chief Executive Officer - Robert P. MauchContinue reading ...
Cencora ( COR ) Q4 Earnings and Revenues Surpass Estimates
Cencora (COR) delivered earnings and revenue surprises of +1.32% and +0.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Agilon Health ( AGL ) Reports Q3 Loss, Tops Revenue Estimates
Agilon (AGL) delivered earnings and revenue surprises of -50.00% and +0.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA to Post Q3 Earnings: What's in Store for the Stock?
Dentsply Sirona's Q3 results may reveal ongoing softness in U.S. demand and orthodontic segments despite steady cost control.
Solventum to Post Q3 Earnings: Is a Beat Likely for the Stock?
Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.
Will Strong Segmental Performance Drive MCK's Top Line in Q2?
McKesson's Q2 results may show steadier growth as strong U.S. pharmaceutical and RxTS momentum drive its expanding top line.
Covenant House Calls for Urgent Action During Youth Homelessness Awareness Month
New York, NY, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- NOVEMBER 3, 2025 - FOR IMMEDIATE RELEASE - NEW YORK, NY
Kailera Therapeutics Appoints Frank Clyburn to Board of Directors
WALTHAM, Mass. and SAN DIEGO, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation therapies for the treatment of obesity, today announced the appointment of Frank ...
Prescription for Beats: 3 Healthcare Stocks Set to Outperform in Q3
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
Countdown to Cencora ( COR ) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Cencora (COR) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Viatris ( VTRS ) Expected to Beat Earnings Estimates: Should You Buy?
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cencora ( COR ) Earnings Expected to Grow: Should You Buy?
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cencora ( COR ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Baxter Q3 Preview: Can Core Segments Deliver Another Solid Quarter?
Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.
Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years - Cencora ( NYSE:COR )
Cencora ( NYSE:COR ) has outperformed the market over the past 10 years by 9.08% on an annualized basis producing an average annual return of 21.58%. Currently, Cencora has a market capitalization of $65.15 billion.
Pharma, Specialty Units Likely to Drive Cardinal Health's Q1 Earnings
CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.
Universal Health to Report Q3 Earnings: Key Estimates to Note
UHS is likely to have posted Q3 revenue and earnings growth, driven by strong hospital and behavioral health segments despite cost pressures.
Will Cencora ( COR ) Beat Estimates Again in Its Next Earnings Report?
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years - Cencora ( NYSE:COR )
Cencora ( NYSE:COR ) has outperformed the market over the past 10 years by 8.64% on an annualized basis producing an average annual return of 21.0%. Currently, Cencora has a market capitalization of $61.96 billion.
Here's Why Cencora ( COR ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio
MCK is transforming from a traditional distributor into a specialty-driven healthcare solutions leader, focusing on oncology, biopharma services and automation while preparing to separate its Medical-Surgical unit.
$1000 Invested In Cencora 5 Years Ago Would Be Worth This Much Today - Cencora ( NYSE:COR )
Cencora ( NYSE:COR ) has outperformed the market over the past 5 years by 11.47% on an annualized basis producing an average annual return of 25.59%. Currently, Cencora has a market capitalization of $58.70 billion.
Why Cencora ( COR ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Does the Market Think About Cencora? - Cencora ( NYSE:COR )
Cencora's COR short interest as a percent of float has fallen 9.62% since its last report. According to exchange reported data, there are now 6.14 million shares sold short, which is 5.45% of all regular shares that are available for trading.
Cencora ( COR ) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
$1000 Invested In Cencora 10 Years Ago Would Be Worth This Much Today - Cencora ( NYSE:COR )
Cencora COR has outperformed the market over the past 10 years by 7.48% on an annualized basis producing an average annual return of 20.51%. Currently, Cencora has a market capitalization of $56.22 billion.
Should SPDR Russell 1000 Low Volatility Focus ETF ( ONEV ) Be on Your Investing Radar?
Style Box ETF report for ...
Is SPDR Russell 1000 Low Volatility Focus ETF ( ONEV ) a Strong ETF Right Now?
Smart Beta ETF report for ...
PACS Group, Inc. ( PACS ) Soars 24.5%: Is Further Upside Left in the Stock?
PACS Group, Inc. (PACS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Hold Cencora Stock in Your Portfolio Now
COR gains from strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose risks.
Here's Why Cencora ( COR ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today - Cencora ( NYSE:COR )
Cencora COR has outperformed the market over the past 10 years by 7.34% on an annualized basis producing an average annual return of 20.01%. Currently, Cencora has a market capitalization of $56.54 billion.
COR vs. MEDP: Which Stock Is the Better Value Option?
Investors with an interest in Medical Services stocks have likely encountered both Cencora ( COR Quick QuoteCOR - ) and Medpace ( MEDP Quick QuoteMEDP - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, HWM, COR and CAKE are some such stocks.
Cencora ( COR ) is an Incredible Growth Stock: 3 Reasons Why
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Looking Into Cencora's Recent Short Interest - Cencora ( NYSE:COR )
Cencora's COR short percent of float has fallen 9.02% since its last report. The company recently reported that it has 6.48 million shares sold short, which is 5.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.81 days to cover their ...
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Climb Bio, Inc. ( CLYM ) Outperforming Other Medical Stocks This Year?
Here is how Climb Bio, Inc. (CLYM) and Cencora (COR) have performed compared to their sector so far this year.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
